Advertisement
Advertisement

EU Signs Deal with GSK for Supply of COVID Potential Drug

By:
Reuters
Updated: Jul 28, 2021, 12:08 UTC

BRUSSELS (Reuters) - The European Union has signed a contract with GlaxoSmithKline for the supply of up to 220,000 treatments of its investigational monoclonal antibody therapy sotrovimab against COVID-19, it said on Wednesday.

Company logo of pharmaceutical company GlaxoSmithKline is seen at their Stevenage facility

The contract has been signed by 16 of the 27 EU states. The drug, which is being assessed by the EU medicines regulator and is not authorized yet, can be used for the treatment of coronavirus patients with mild symptoms who do not require supplemental oxygen, the Commission said.

(Reporting by Francesco Guarascio @fraguarascio, editing by Louise Heavens)

About the Author

Reuterscontributor

Reuters, the news and media division of Thomson Reuters, is the world’s largest international multimedia news provider reaching more than one billion people every day. Reuters provides trusted business, financial, national, and international news to professionals via Thomson Reuters desktops, the world's media organizations, and directly to consumers at Reuters.com and via Reuters TV. Learn more about Thomson Reuters products:

Did you find this article useful?

Advertisement